Navigation Links
Oncobiologics and inVentiv Health Form Strategic Partnership around Biosimilars

CRANBURY, N.J., Aug. 6, 2013 /PRNewswire/ -- Oncobiologics, Inc. and inVentiv Health today announced a broad strategic partnership around clinical development for all assets in Oncobiologic's pipeline.  The scope of the partnership is global and will initially focus on biosimilar assets, and could be expanded to include innovative molecules.  Through the partnership, inVentiv Health will provide leadership and execution for clinical studies, as well as the corresponding bioanalytical support for those trials.  As the assets are commercialized, the partnership will be broadened to include inVentiv's significant commercialization capabilities in select countries.  This will position Oncobiologics attractively in seeking future commercial partners.

The current biosimilar assets include generic versions of Humira®, Rituxan®, Avastin®, Herceptin® and Erbitux®. These biologics are the most popular therapies in the world for their respective cancer and immune-disease indications, representing annual global revenue of more than $40 billion.

"After an exhaustive global review of potential partners, we selected the broad-scale inVentiv platform as an important differentiator for our program as this partnership spans both clinical and bioanalytical development as well as commercialization of our biosimilar assets.  inVentiv is able to take the scope of these agreements to a much broader level by working across the full development life cycle of each biosimilar and innovator product while preparing for a successful market launch. With their willingness to share in the risk/reward of our development programs, our firms are a perfect fit, both technically and culturally," said Oncobiologics Founder & CEO, Pankaj Mohan, Ph.D.

Ray Hill, President, inVentiv Health Clinical added, "We are thrilled to partner with Oncobiologics and to be a part of their highly capable biosimilars consortium.  With their recent global partnering successes, we look forward to helping Oncobiologics bring their biosimilar assets through clinical trials and into the marketplace. By joining their fully-integrated CMC capabilities with inVentiv's broad clinical and commercial expertise, we are creating a venture that is truly greater than the sum of its parts."

About Oncobiologics, Inc.
Oncobiologics is a privately-held biopharmaceutical company that has developed a pipeline of biosimilars and is developing next generation biotherapeutics focused on clinically validated targets in the therapeutic areas of oncology, immuno-oncology, and immunology. Formed by a team of leading industry experts from firms such as Eli Lilly, Bristol-Myers Squibb, Amgen, Genentech, Merck and Pfizer, Oncobiologics operates from a state-of-the-art 30,000 sq. ft. R&D facility in Cranbury, NJ. For more information, please visit

About inVentiv Health Clinical
inVentiv Health Clinical is a leading provider of global drug development services to pharmaceutical, biotechnology, generic drug, and medical device companies, offering therapeutically specialized capabilities for Phase I-IV clinical development, bioanalytical services, and strategic resourcing from a single clinical professional to an entire functional team.  With 7,000 passionate employees operating in more than 70 countries, inVentiv Health Clinical works to accelerate high quality drug development programs of all sizes around the world.  http://www.inventivhealthclinical.comContact:Rick GregoryDirector of Marketing & CommunicationsOncobiologics,

SOURCE Oncobiologics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Huahai and Oncobiologics Create Broad Biosimilars Partnership
2. Oncobiologics and Boston Oncology Team Up to Deliver Biosimilar Therapies for Cancer and Immune Disease to Middle East and North African Markets
3. inVentiv Health Partners With Medikly To Speed Clinical Trials By Accelerating The Recruitment Of Investigators
4. inVentiv Health Forms Strategic Alliance With Bell Medical Solutions, One Of Japans Top Clinical Research Organizations
5. PharmaNet/i3 Renamed inVentiv Health Clinical
6. inVentiv Health Strengthens Clinical Leadership Team
7. inVentiv Medical Management Forms Partnership with Vital Decisions
8. Frost & Sullivan Analyzes Emerging Opportunities for Stakeholders in the Transforming Healthcare Industry
9. Human Circuit Recognized as Industry Leader in Commercial Integrator Magazines Business Series as a Top 5 Healthcare Market Media Integrator for 2013
10. The Center for Ultrasound Research and Education (CURE) Receives Institutional Accreditation from the Accrediting Bureau of Health Education Schools
11. Indonesias Healthcare Reforms Create Opportunities But Also Present New Market Access Hurdles for the Multinational Pharmaceutical Industry
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015  Trovagene, Inc. (NASDAQ: ... announced that Chief Executive Officer Antonius Schuh, Ph.D., is ... th Annual Piper Jaffray Healthcare Conference. ... New York Palace Hotel in New York ... p.m. EST. Mr. Schuh will be available for one-on-one ...
(Date:11/25/2015)... Nov. 25, 2015 Endo International plc (NASDAQ: ... Silva , President and CEO, will discuss corporate updates at ... New York on Wednesday, December 2, ... Click on Investor Relations, and then the link to the ... presentation,s start time to visit the site and download any ...
(Date:11/25/2015)... November 25, 2015 Asia ... to which BioLight and the New Investors will make ... ("IOPtima") via a private placement. The financing will help ... IOPtimate™ system used in the treatment of glaucoma, as ... for the IOPtimate™ system with the U.S. Food and ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... Beddit® has launched a new Android app ... new app features a more intuitive SleepScore™ that rates sleep quality on a 100-point ... SleepScore is created by a proprietary algorithm. Beddit analyzes the data to provide an ...
(Date:11/25/2015)... ... November 25, 2015 , ... “While riding the bus, ... from Bronx, N.Y. “I thought there had to be a convenient and comfortable way ... , The PROTECTOR enables disabled individuals to safely travel during cold or inclement weather. ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... announces the nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care for ... The Periwinkle Pioneers, nominated by the public, will receive special recognition throughout 2016 ...
(Date:11/25/2015)... ... 25, 2015 , ... An unlikely combination of recycled plastic ... for homeless people to have a more dignified and comfortable night’s sleep. , ... are repurposing plastic bags into sleeping mats for the homeless. The project, ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... has focused on providing comprehensive solutions involving adult stem cell therapies to patients ... officially deemed the “Regenestem” name as a Registered Trademark (RTM). , Organizations are ...
Breaking Medicine News(10 mins):